Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors
about
The SH2 domain regulates c-Abl kinase activation by a cyclin-like mechanism and remodulation of the hinge motionFluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Functionc-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in SolutionDefying c-Abl signaling circuits through small allosteric compounds.Differential sensitivity of Src-family kinases to activation by SH3 domain displacement.NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.Applications of hydrogen/deuterium exchange MS from 2012 to 2014.Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases.Structure and dynamic regulation of Abl kinases.Management of chronic myeloid leukemia in blast crisis.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growthAtomic view of the energy landscape in the allosteric regulation of Abl kinase.Single nucleotide editing without DNA cleavage using CRISPR/Cas9-deaminase in the sea urchin embryo.The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility.Selective inhibition of the myeloid Src-family kinase Fgr potently suppresses AML cell growth in vitro and in vivo.
P2860
Q28543640-35DF7E76-29A1-4AF4-9A4B-9C60143E0F4FQ28546849-B6650E87-7473-4491-8B16-1DC3BD857EB5Q30008916-8D730BF4-ECCF-443C-933B-89F054F06FD5Q30009269-2C460398-5F50-4B76-BB25-9C782467D4F5Q30009328-68E8B881-A9AF-4982-8343-88FFBA0F60DEQ30009530-B60DAA0A-574F-4EE6-8071-55E7665D5529Q34552575-33C89DC1-F544-4DF5-8576-1730F7EF831BQ34870033-57C4FCB9-5C86-42E5-98DE-CD1D39C9119AQ35043382-D5AABD29-4007-4D5B-A512-C46F7FB284F7Q36635994-357FD00D-ABF6-4F48-8E3D-DE1E8A128592Q38392682-812FA444-1D9F-4A72-B15C-D325EF2239A1Q38845834-3D3AB5FE-5002-4FE7-A44B-F91DA0B025B8Q41071486-6795E7E3-1817-4B7F-B66F-8FEC4E724792Q47748395-1344A80E-7FCD-4185-B4EC-C60D49584E6DQ48148740-22543073-495D-4A75-B808-8B33BA080502Q52655033-59BD9040-8F86-4135-8D05-33CB1F0F0755Q54109758-74377A88-3692-4D56-87FF-AFC860275763
P2860
Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Enhanced SH3/linker interactio ...... y to small molecule inhibitors
@ast
Enhanced SH3/linker interactio ...... y to small molecule inhibitors
@en
type
label
Enhanced SH3/linker interactio ...... y to small molecule inhibitors
@ast
Enhanced SH3/linker interactio ...... y to small molecule inhibitors
@en
prefLabel
Enhanced SH3/linker interactio ...... y to small molecule inhibitors
@ast
Enhanced SH3/linker interactio ...... y to small molecule inhibitors
@en
P2093
P2860
P3181
P356
P1476
Enhanced SH3/linker interactio ...... y to small molecule inhibitors
@en
P2093
Roxana E Iacob
Shoghag Panjarian
Shugui Chen
Thomas E Smithgall
Thomas E Wales
P2860
P304
P3181
P356
10.1074/JBC.M112.431312
P407
P577
2013-01-09T00:00:00Z